Cargando…

T‐cell redirecting bispecific antibodies in multiple myeloma: Current landscape and future directions

T‐cell engaging bispecific antibodies (BsAbs) have substantial activity in heavily pretreated patients with multiple myeloma (MM). The overall response rate obtained with B‐cell maturation antigen (BCMA)‐targeting BsAbs is approximately 60%–70%, including a high proportion of patients achieving very...

Descripción completa

Detalles Bibliográficos
Autores principales:	O'Neill, Chloe, van de Donk, Niels W. C. J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10435697/ https://www.ncbi.nlm.nih.gov/pubmed/37601851 http://dx.doi.org/10.1002/jha2.729

Ejemplares similares

T-cell redirecting bispecific and trispecific antibodies in multiple myeloma beyond BCMA
por: van de Donk, Niels W.C.J., et al.
Publicado: (2023)

Current State of the Art and Prospects of T Cell-Redirecting Bispecific Antibodies in Multiple Myeloma
por: Hosny, Mashhour, et al.
Publicado: (2021)

T-cell redirecting bispecific antibodies targeting BCMA for the treatment of multiple myeloma
por: Verkleij, Christie P.M., et al.
Publicado: (2020)

Current landscape and future directions of bispecific antibodies in cancer immunotherapy
por: Wei, Jing, et al.
Publicado: (2022)

Safety and efficacy of T-cell-redirecting bispecific antibodies for patients with multiple myeloma: a systematic review and meta-analysis
por: Noori, Maryam, et al.
Publicado: (2023)

Enhancing the antitumor potency of T cells redirected by bispecific antibodies
por: Chang, Chien-Hsing, et al.
Publicado: (2017)

Development of a T cell-redirecting bispecific antibody targeting B-cell maturation antigen for the suppression of multiple myeloma cell growth
por: Huo, Jianxin, et al.
Publicado: (2022)

Bispecific Antibodies for Multiple Myeloma: A Review of Targets, Drugs, Clinical Trials, and Future Directions
por: Caraccio, Chiara, et al.
Publicado: (2020)

Influence of the bispecific antibody IgG subclass on T cell redirection
por: Kapelski, Stephanie, et al.
Publicado: (2019)

Current Indications and Future Landscape of Bispecific Antibodies for the Treatment of Lung Cancer
por: Arasanz, Hugo, et al.
Publicado: (2023)

Immunotherapy of Acute Lymphoblastic Leukemia and Lymphoma With T Cell–Redirected Bispecific Antibodies
por: Lussana, Federico, et al.
Publicado: (2021)

Monoclonal and Bispecific Anti-BCMA Antibodies in Multiple Myeloma
por: Dalla Palma, Benedetta, et al.
Publicado: (2020)

Bispecific antibodies for non-Hodgkin’s lymphomas and multiple myeloma
por: Castaneda-Puglianini, Omar, et al.
Publicado: (2021)

Regulatory T cells are redirected to kill glioblastoma by an EGFRvIII-targeted bispecific antibody
por: Choi, Bryan D, et al.
Publicado: (2013)

Bispecific antibodies redirect synthetic agonistic receptor modified T cells against melanoma
por: Märkl, Florian, et al.
Publicado: (2023)

Monoclonal Antibodies and Antibody Drug Conjugates in Multiple Myeloma
por: Radocha, Jakub, et al.
Publicado: (2021)

Redirecting T-cell Activity with Anti-BCMA/Anti-CD3 Bispecific Antibodies in Chronic Lymphocytic Leukemia and Other B-cell Lymphomas
por: Martens, Anne W.J., et al.
Publicado: (2022)

Engineering Immune Cells for in vivo Secretion of Tumor-Specific T Cell-Redirecting Bispecific Antibodies
por: Blanco, Belén, et al.
Publicado: (2020)

Novel potent anti-STEAP1 bispecific antibody to redirect T cells for cancer immunotherapy
por: Lin, Tsung-Yi, et al.
Publicado: (2021)

Bispecific Antibody Format and the Organization of Immunological Synapses in T Cell-Redirecting Strategies for Cancer Immunotherapy
por: Carrasco-Padilla, Carlos, et al.
Publicado: (2022)

Bispecific Antibodies: A New Era of Treatment for Multiple Myeloma
por: Zhou, Xiang, et al.
Publicado: (2020)

Bispecific antibodies in multiple myeloma treatment: A journey in progress
por: Cho, Shih-Feng, et al.
Publicado: (2022)

Infectious complications of bispecific antibody therapy in patients with multiple myeloma
por: Sim, Beatrice Z., et al.
Publicado: (2023)

Resistance Mechanisms towards CD38−Directed Antibody Therapy in Multiple Myeloma
por: Franssen, Laurens E., et al.
Publicado: (2020)

Emerging Role of Antibody-Drug Conjugates and Bispecific Antibodies for the Treatment of Multiple Myeloma
por: Tai, Waqqas, et al.
Publicado: (2022)

MEK Inhibitor Augments Antitumor Activity of B7-H3-Redirected Bispecific Antibody
por: Li, Hongjian, et al.
Publicado: (2020)

Efficient and Highly Specific Gene Transfer Using Mutated Lentiviral Vectors Redirected with Bispecific Antibodies
por: Parker, Christina L., et al.
Publicado: (2020)

Bispecific Antibody Inhalation Therapy for Redirecting Stem Cells from the Lungs to Repair Heart Injury
por: Liu, Mengrui, et al.
Publicado: (2020)

Conduit CAR: Redirecting CAR T-Cell Specificity with A Universal and Adaptable Bispecific Antibody Platform
por: Borrok, M. Jack, et al.
Publicado: (2022)

A Focus on CAR T-Cell Therapy and Bispecific Antibodies in Multiple Myeloma
por: Catamero, Donna, et al.
Publicado: (2022)

Bispecific Antibodies in Multiple Myeloma: Opportunities to Enhance Efficacy and Improve Safety
por: Swan, Dawn, et al.
Publicado: (2023)

CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance
por: van de Donk, Niels W.C.J., et al.
Publicado: (2018)

P862: A PHASE 1 FIRST-IN-HUMAN MONOTHERAPY STUDY OF ABBV-383, A BCMA × CD3 BISPECIFIC T-CELL–REDIRECTING ANTIBODY, IN RELAPSED/REFRACTORY MULTIPLE MYELOMA
por: Weisel, Katja, et al.
Publicado: (2023)

Drug Conjugated and Bispecific Antibodies for Multiple Myeloma: Improving Immunotherapies off the Shelf
por: Barilà, Gregorio, et al.
Publicado: (2021)

Bispecific BCMA-CD3 Antibodies Block Multiple Myeloma Tumor Growth
por: Wu, Lijun, et al.
Publicado: (2022)

Kinetics of Humoral Immunodeficiency With Bispecific Antibody Therapy in Relapsed Refractory Multiple Myeloma
por: Hammons, Lindsay R., et al.
Publicado: (2022)

The Role of Bispecific Antibodies in Relapsed Refractory Multiple Myeloma: A Systematic Review
por: Khanam, Razwana, et al.
Publicado: (2023)

Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis
por: Mazahreh, Farah, et al.
Publicado: (2023)

A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen × CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple Myeloma
por: D'Souza, Anita, et al.
Publicado: (2022)

Generation of T-cell-redirecting bispecific antibodies with differentiated profiles of cytokine release and biodistribution by CD3 affinity tuning
por: Haber, Lauric, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_feufr7i71lcv3mtor2mrcarj5i